A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days. Participants will be randomized to one of 4 treatment groups: placebo, KYN-5356 low dose, KYN-5356 medium dose, KYN-5356 high dose. Participants will be admitted to the clinic on Day -3 and will remain in residence at the clinic for 32 days, from baseline through the treatment period. Participants will be administered investigational medicinal product on Days 1 through 28.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Cognitive Impairment Associated With Schizophrenia (CIAS)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 55 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Kynexis B.V.

Last updated on ClinicalTrials.gov

June 23, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites